N6-Benzyladenosine (Synonyms: Benzyladenosine) |
رقم الكتالوجGC67272 |
N6-Benzyladenosine هو ناهض لمستقبلات الأدينوزين ، وله نشاط خلوي. يوقف N6-Benzyladenosine دورة الخلية في مرحلة G0 / G1 ويحفز موت الخلايا المبرمج. N6-Benzyladenosine له أيضًا تأثير مثبط على T. gondii adenosine kinase والورم الدبقي.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4294-16-0
Sample solution is provided at 25 µL, 10mM.
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma[1]-[5].
N6-benzyladenosine suppresses the clonogenic activity and the growth of different neoplastic cells[2].
N6-benzyladenosine results cell morphology alteration and actin cytoskeleton disorganization in T24 cell[2].
N6-benzyladenosine (10 μM; 24 h) is a potent inductor of apoptosis, and belongs to apoptotic systems with distinct caspase-3 and caspase-9 activation[3].
N6-benzyladenosine (0-100 μM; 24 h) induces chromatin condensation, formation of apoptotic bodies, and cleavage of DNA to nucleosomal fragments in a dose-dependent manner[3].
N6-benzyladenosine acts as a selective anti-toxoplasma agent with binding affinity to T. gondii adenosine kinase (apparent Km =179.8 μM), over human adenosine kinase[4].
N6-benzyladenosine (0-50 μM) shows weak inhibition against adenosine kinase deficient (TgAKS3) strains of Toxoplasma gondii[4].
N6-benzyladenosine (compound 2) (0.3-20 μM) exerts anti-glioma activity by interfering with the mevalonate pathway and inhibiting FPPS (Farnesyl pyrophosphate synthase) [5].
Apoptosis Analysis[3]
Cell Line: | HL-60 |
Concentration: | 10 μM |
Incubation Time: | 24 hours |
Result: | Induced cell apoptosis by increasing caspase-3 (DEVDase) as well as caspase-9 (LEHDase) activity, indicating an apoptotic systems with distinct caspase-3/9 activation. |
Apoptosis Analysis[5]
Cell Line: | U87MG human glioma cell line. |
Concentration: | 0.3, 0.6, 1.2, 2.5, 5, 10, 20 μM |
Incubation Time: | 48 hours |
Result: | Inhibited glioma growth by interfering with the mevalonate pathway and inhibiting FPPS. |
[1]. Kaminek M, et al. Cytokinin activities of N6-benzyladenosine derivatives hydroxylated on the side-chain phenyl ring. Journal of Plant Growth Regulation. 1987. 6(2):113.
[2]. Castiglioni S, et al. N6-isopentenyladenosine and its analogue N6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells. Anticancer Agents Med Chem. 2013 May;13(4):672-8.
[3]. Mlejnek P. Caspase inhibition and N6-benzyladenosine-induced apoptosis in HL-60 cells. J Cell Biochem. 2001;83(4):678-89.
[4]. Kim YA, et al. Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. Biochem Pharmacol. 2007 May 15;73(10):1558-72.
[5]. Grimaldi M, et al. NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity. Bioorg Chem. 2020 May;98:103449.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *